Arabic Arabic English English French French German German
dark

Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug

The FDA placed a clinical hold on Magenta’s clinical program for acute myeloid leukemia and myelodysplastic syndrome, which made its shares drop nearly 7% this morning.  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Digital Health Funding Is Higher Than Ever Before

Next Post

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Related Posts
Total
0
Share